**Table VI.** Regression analysis results (adjusted and unadjusted) in detail

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Days to NE** | | | | | | | | **Days to PE** | | | | | | |
| **N [%]** | **N [%] ≤ 10 days 14 (37.8%)** | | | | | | | **N [%] ≤ 15 days 22 (59.45%)** | | | | | | |
| **N [%] > 10 days 23 (62.2%)** | | | | | | | **N [%] > 15 days 15 (40.55%)** | | | | | | |
| **Unadjusted** | | | | **Adjusted** | | | **Unadjusted** | | | | **Adjusted** | | |
| **OR** | **95% CI** | ***p*-value** | **Constant *p*-value** | **OR** | **95% CI** | ***p*-value** | **OR** | **95% CI** | ***p*-value** | **Constant *p*-value** | **OR** | **95% CI** | ***p*-value** |
| TSH | ≤ 2.89 mU/L | 30 (81.08%) | Reference | | | | | | | Reference | | | | | | |
| > 2.89 mU/L | 7 (18.92%) | 1.67 | 0.28,10.03 | 0.577 | 0.277 | 6.44 | 0.25,67.47 | 0.262 | 5 | 0.82,30.46 | 0.081 | 0.074 | 14.32 | 1.88,33.11 | 0.041 |
| Free T4 | ≤ 1.4 ng/dL | 31 (83.78%) | 1.82 | 0.31,10.58 | 0.506 | 1 | 1.26 | 0.12,13.45 | 0.846 | 4.12 | 0.43,39.48 | 0.22 | 0.142 | 3.61 | 0.15,34.47 | 0.432 |
| > 1.4 ng/dL | 6 (16.22%) | Reference | | | | | | | Reference | | | | | | |
| Free T3 | ≤ 2.8 pg/mL | 29  (78.38%) | 0.98 | 0.2,4.94 | 0.982 | 0.484 | 0.63 | 0.09,4.69 | 0.653 | 0.32 | 0.06,1.6 | 0.164 | 0.484 | 0.19 | 0.02,1.64 | 0.132 |
| > 2.8 pg/mL | 8 (21.62%) | Reference | | | | | | | Reference | | | | | | |
| Age | > 40 years | 22  (59.46%) | 1.17 | 0.3,4.49 | 0.823 | 0.442 | 1.46 | 0.2,10.73 | 0.708 | 1.04 | 0.27,3.96 | 0.956 | 0.442 | 2.2 | 0.21,22.66 | 0.506 |
| ≤ 40 years | 15  (40.54%) | Reference | | | | | | | Reference | | | | | | |
| Sex | Male | 20  (54.05%) | 5.71 | 1.33,24.62 | 0.019 | 0.469 | 8.58 | 1.15,64.13 | 0.036 | 1.5 | 0.4,5.66 | 0.55 | 0.232 | 1.04 | 0.17,6.47 | 0.965 |
| Female | 17  (45.95%) | Reference | | | | | | | Reference | | | | | | |
| HSCT type | Allogeneic | 8 (21.62%) | 1.02 | 0.2,5.13 | 0.982 | 0.198 | 3.3 | 0.21,50.95 | 0.39 | 3.17 | 0.63,16.05 | 0.164 | 0.1 | 5.67 | 0.38,84.53 | 0.208 |
| Autologous | 29 (78.38%) | Reference | | | | | | | Reference | | | | | | |
| Disease | Leukemia | 7 (20.0%) | 0.9 | 0.14,5.48 | 0.899 |  |  |  |  | 2 | 0.32,12.33 | 0.455 |  |  |  |  |
| Lymphoma | 13 (37.15%) | 1.5 | 0.31,7.19 | 0.612 | 0.442 | 4.43 | 0.37,52.87 | 0.24 | 0.67 | 0.14,3.19 | 0.612 | 0.442 | 1.02 | 0.12,8.65 | 0.99 |
| MM | 15 (42.9%) | Reference | | | | | | | Reference | | | | | | |
| CD34+ cell count | ≤ 2 × 106/kg | 15 (40.5%) | 2.06 | 0.43,9.8 | 0.363 |  | 1.44 | 0.18,11.82 | 0.735 | 0.67 | 0.15,3.01 | 0.598 |  | 0.57 | 0.07,4.5 | 0.59 |
| 2–3 × 106/kg | 8 (21.6%) | 0.75 | 0.13,4.29 | 0.746 | 0.594 | 0.22 | 0.01,4.65 | 0.328 | 1.33 | 0.23,7.63 | 0.746 | 0.594 | 0.66 | 0.04,12.67 | 0.784 |
| >3 × 106/kg | 14 (37.8%) | Reference | | | | | | | Reference | | | | | | |
| Constant |  |  | 0.23 | | | | 0.456 | | |  | 0.28 | | | 0.583 | | |

NE — neutrophil engraftment; PE — platelet engraftment; N — number; OR — odds ratio; CI — confidence interval; TSH — thyroid stimulating hormone; T4 — thyroxine; T3 — triiodothyronine; HSCT — hematopoietic stem cell transplantation; MM — multiple myeloma